Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al.|The Lancet|2023Cited by 181
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Vikas Gupta, James Davies et al.|Biology of Blood and Marrow Transplantation|2015Cited by 142
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben A. Mesa, Srđan Verstovšek, Claire Harrison et al.|Leukemia|2022Cited by 63
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based studyAytug Kizilors, Hugues de Lavallade, Elena Crisà et al.|The Lancet Haematology|2019Cited by 56
Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UKNatalia Curto‐García, Claire Harrison, Andrew J. Doyle et al.|British Journal of Haematology|2020Cited by 31